IDEAYA Biosciences (IDYA) Operating Margin (2020 - 2026)
IDEAYA Biosciences (IDYA) posted Operating Margin of 1654.63% for Q1 2026, down 90.29% sequentially from 869.53% in Q4 2025.
IDEAYA Biosciences (IDYA) Operating Margin (2020 - 2026) Analysis & Trends
IDEAYA Biosciences has reported Operating Margin for 7 years, with the latest figure at 1654.63% in Q1 2026.
- Quarterly Operating Margin changed N/A year-over-year to 1654.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 78.99% (changed N/A YoY) and the FY2025 annual result came in at 72.84%, up 459823.0% from the prior year.
- Operating Margin fell to 1654.63% in Q1 2026 per IDYA's latest filing, from 869.53% in the prior quarter.
- Over five years, Operating Margin peaked at 52.18% in Q3 2025 and troughed at 2059.11% in Q4 2024.
- A 5-year average of 703.2% and a median of 537.28% in 2022 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin slumped 99035 bps in 2024, then jumped 118959 bps in 2025.
- Over 5 years, Operating Margin stood at 657.46% in 2022, then plunged by 63 bps to 1068.77% in 2023, then sank by 93 bps to 2059.11% in 2024, then surged by 58 bps to 869.53% in 2025, then slumped by 90 bps to 1654.63% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 1654.63%, 869.53%, and 52.18% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | -1,380.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,380.73% |
| Mar 31, 2026 | -1,654.63% |
| Dec 31, 2025 | -869.53% |
| Sep 30, 2025 | 52.18% |
| Dec 31, 2024 | -2,059.11% |
| Dec 31, 2023 | -1,068.77% |
| Sep 30, 2023 | -417.09% |
| Jun 30, 2023 | -922.94% |
| Mar 31, 2023 | -333.49% |
| Dec 31, 2022 | -657.46% |
| Sep 30, 2022 | 2.22% |
| Jun 30, 2022 | -384.53% |
| Mar 31, 2022 | -125.19% |
| Dec 31, 2021 | -620.16% |
| Sep 30, 2021 | -130.49% |
| Jun 30, 2021 | -126.21% |
| Mar 31, 2021 | -126.05% |
| Dec 31, 2020 | -49.95% |
| Sep 30, 2020 | -55.72% |